@article{96d35ab8b0954830bb7300539a97a5a2,
title = "Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Final analysis of the GioTag study",
abstract = "Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. Clinical Trial Registration: NCT03370770 (ClinicalTrials.gov.",
keywords = "EGFR, NSCLC, afatinib, osimertinib",
author = "Hochmair, {Maximilian J.} and Alessandro Morabito and Desiree Hao and Yang, {Cheng Ta} and Soo, {Ross A.} and Yang, {James C.H.} and Rasim Gucalp and Balazs Halmos and Angela M{\"a}rten and Tanja Cufer",
note = "Funding Information: This study was supported by Boehringer Ingelheim. MJ Hochmair reports personal fees from Speakers honorarium Boehringer Ingelheim, AstraZeneca and Roche. A Morabito has received honoraria from Boehringer Ingelheim, Roche, AstraZeneca, Pfizer, MSD and Bristol Myers Squibb. D Hao reports research funding and consultancy from Boehringer Ingelheim and Astra Zeneca. RA Soo reports grants and personal fees from Astra Zeneca, personal fees from BMS, Boehringer Ingelheim, Celgene, Lilly, Merck, Novartis, Pfizer, Roche, Taiho and Ignyta. JC-H Yang reports personal fees from Boehringer Ingelheim, Eli Lilly, Roche/Genentech, Chugai, Astellas, MSD, Merck Serono, Pfizer, Novartis, Celgene, Merrimack, Yuhan Pharmaceuticals, Bristol Myers Squibb, Ono Pharmaceuticals, Daiichi Sankyo, AstraZeneca, Hansoh Pharmaceuticals and Takeda Pharmaceuticals. B Halmos reports grants and personal fees from Boehringer Ingelheim, Astra Zeneca, Pfizer, Novartis and Takeda, personal fees from Genentech/Roche, and grants from Merck. A M{\"a}rten reports employment with Boehringer Ingelheim. T Cufer reports consultancy and honoraria from AstraZeneca, Roche, Pfizer, MSD, Bristol Myers Squibb and Boehringer Ingelheim. C-T Yang and R Gucalp report no competing interests. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Funding Information: Medical writing assistance was provided by J Saunders, of GeoMed, an Ashfield company, part of UDG Healthcare plc and was supported financially by Boehringer Ingelheim. Publisher Copyright: {\textcopyright} 2020 Maximilian J. Hochmair and other authors.",
year = "2020",
month = dec,
doi = "10.2217/fon-2020-0740",
language = "English (US)",
volume = "16",
pages = "2799--2808",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "34",
}